Clinical Trial Update: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chidamide in combination with envafolimab for PD-1 inhibitor-resistant advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chidamide (chidamide)
• Envafolimab (envafolimab)

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED